Trial reportEuropean journal of nuclear medicine and molecular imaging2024
Feasibility and therapeutic potential of [
Trial report in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic potential of FAPI RLT in oncology: A systematic review.Theranostics · 2025Pooled it
- 177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Feasibility and therapeutic potential of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Correlation of apparent diffusion coefficient, FAP expression in IHC and [EJNMMI research · 2026Article
- The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review.Annals of nuclear medicine · 2026Review
- Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review.The British journal of radiology · 2026Review
- Dual-tracer PET/CT and cocktail therapy with [European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic value of [⁶⁸Ga]Ga-FAPI PET imaging in patients with sarcoma.European journal of nuclear medicine and molecular imaging · 2026Article
- FAP-Targeted Radionuclide Therapy: Mechanisms, Clinical Applications, and Combination Strategies.Biomedicines · 2026Review
- Head-to-Head Comparison of Monomeric, Homodimeric, and Heterodimeric Fibroblast Activation Protein-Targeting Radioligands Based on Small Molecule Inhibitor and Cyclic Peptide.ACS pharmacology & translational science · 2026Article
- Swin UNETR-based prediction of [BMC medical imaging · 2026Article
- Preclinical evaluation of novelAnnals of nuclear medicine · 2026Article
- Observational
- Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.European journal of nuclear medicine and molecular imaging · 2026Review
- Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application.Molecular imaging and biology · 2026Review
- Theranostics in Sarcoma: A Critical Review of Current Evidence and Future Potential.Current treatment options in oncology · 2026Review
- Combined antitumor activity of [EJNMMI research · 2026Article
- The Current Status of Radionuclide Tumor Targeting Diagnosis and Therapy Based on FAP-2286: From Preclinical Studies to Clinical Application.Molecular diagnosis & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe unique expression pattern of fibroblast activation protein (FAP) in stromal and tumor cells, particularly in sarcomas, and its absence in normal tissues, have positioned it as a promising theragnostic approach for the detection and treatment of various cancer types. The objective of this prospective study is to assess the feasibility, safety, biodistribution, and therapeutic efficacy of [ PATIENTS AND
methodsEight patients with advanced metastatic sarcoma, who were unresectable or had experienced disease recurrence following conventional treatments, underwent PTRT (peptide-targeted radionuclide therapy) using [
resultsAfter four cycles of PTRT with [
conclusion[
Indexed as
Identifiers
39060377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.